Vera Therapeutics

Vera Therapeutics

Biotechnology
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

$1.9B

Market Cap • 10/14/2026

2016

(10 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

19,4

EPS

—

Market Cap

Market Cap

1,9B

EV

1,5B

EV/Revenue

0

EV/EBITDA

-3,6

EV/EBIT

-3,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-16,1%

Total Yield

-16,1%

Payout

0%

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

48,1%

Capex/OCF

-0,1%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

48,7%

CAGR Net Income 5Y

48,6%

CAGR EPS 5Y

-48,6%

CAGR OCF 5Y

52,1%

Leverage

N.D./EBITDA

1

Debt/Equity

0%

Current Ratio

0

Quick Ratio

0

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium